Moleculent
PrivateLast Round
Series A
Extension
Apr 30, 2026
Total Funding Raised
$46M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Moleculent operates in Healthcare & Life Sciences and is based in Solna. Its latest recorded funding round was a Series A Extension round in April 2026.
Moleculent is a biotechnology company that develops a functional profiling platform to map cell-cell communication directly within clinical tissue.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Usage-Based SaaS
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Moleculent Comparables
Compare Moleculent with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pixelgen Technologies | 86% | |
| Takara Holdings Inc. | 84% | |
| Stellaromics | 82% |
For institutional investors. Book with your work email.
Moleculent Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Apr 30, 2026 | ||||
| Series A | Jun 11, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Moleculent Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Rubicon Healthcare Partners | Series A Extension |
| Eir Ventures | Series A Extension, Series A |
| ARCH Venture Partners | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Monthly visitors increased 1292% MoM, reaching 5.2K.
- Apr 30, 2026
$20M raised with Rubicon Healthcare Partners leading.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesNov 3, 2026
Moleculent introduces Glimt, an automated platform that detects cell-cell interactions directly in FFPE tissue, in Sweden on Nov 3rd '26; the platform is available to selected academic and biopharma labs through its early access program.
For institutional investors. Book with your work email.
Moleculent Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Moleculent's valuation, stock price, and market status.
Is Moleculent a public or private company?
Moleculent is a private company.
What is the current stock price of Moleculent?
Moleculent is a private company, so its shares have no public market price. Caplight tracks Moleculent's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Moleculent worth (valuation)?
Valuation information for Moleculent is not publicly available.
Can I buy Moleculent stock?
Moleculent shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Moleculent's last funding round?
Moleculent's most recent funding round was Series A Extension on April 30, 2026.
Who are the main investors in Moleculent?
Key investors in Moleculent include Rubicon Healthcare Partners, Eir Ventures, ARCH Venture Partners.
Will Moleculent IPO soon?
No public IPO plans have been announced for Moleculent.
How can I track Moleculent secondary market activity?
Caplight tracks bids, offers, and trades in Moleculent's shares on secondary markets.